Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Shelf Supplement

<< Previous

Bullboard Posts

Next >>

Comment by Pragmatiston Feb 19, 2021 6:35pm

163 Views

Post# 32616450

RE:RE:Shelf Supplement

Hideaway wrote: If they are selling to the public at $6 per share, does this include the warrants? If not, can one purchase the warrants seperately? Hope someone on Board can educate me and, if shares and/or warrants are avaiable how does a small investor participate?TIA.

It includes the warrants. Regarding warrant purchases separately, this is addressed in the Supplement, and if I recall, it specifies that the warrants cannot be sold separately, such as on the open market. I think it is too late to participate now if you have not already put an order in with your broker.

<< Previous

Bullboard Posts

Next >>

Cannara reports record growth and profitability in Q4 2023